- 专利标题： Method of treating a person afflicted with COVID-19 and pharmaceutical formulation including dapsone
-
申请号： US17955337申请日： 2022-09-28
-
公开(公告)号： US11826323B2公开(公告)日： 2023-11-28
- 发明人: Houfar Sekhavat , Satish Asotra
- 申请人： Pulmonem Inc.
- 申请人地址： CA Dieppe
- 专利权人： PULMONEM INC.
- 当前专利权人： PULMONEM INC.
- 当前专利权人地址： CA Dieppe
- 代理机构： Smart & Biggar LP
- 主分类号： A61K31/145
- IPC分类号： A61K31/145 ; A61K9/00 ; A61K9/06 ; A61K9/14 ; A61K31/65 ; A61K31/7052 ; A61K47/14 ; A61K47/44 ; A61P11/00 ; A61K31/10 ; A61K47/42 ; A61M15/00
摘要：
A method for treating patients with COVID-19 and/or other respiratory conditions includes administering eighty-five milligrams of dapsone twice daily for twenty-one days. A variety of dapsone formulations and delivery devices are disclosed, including an inhaler, nasal spray, nasal gel, otic formulation, intravenous formulation, oral solution, oral suspension, patch and suppository.
公开/授权文献
信息查询
